Clinical and Translational Oncology

, Volume 12, Issue 9, pp 629–633 | Cite as

Fifty-one Kaposi sarcoma patients

  • Mutlu DoganEmail author
  • Lutfi Dogan
  • Feyyaz Ozdemir
  • Nuriye Yildirim Ozdemir
  • Hasan Senol Coskun
  • Ulku Yalcintas Arslan
  • Guze Ozal
  • Gungor Utkan
  • Ahmet Demirkazik
  • Fazil Aydin
  • Nurullah Zengin
  • Fikri Icli
Research Articles



Kaposi sarcoma (KS) is a mesenchymal tumor originating from lymphatic endothelial cells. Immunsupressive patients have higher risk for KS. HHV-8 has a role in immunpathogenesis of KS.


Evaluation of demographical properties with tumor characteristics and treatment modalities of KS.

Material and method

Histopathologically documented KS patients were evaluated retrospectively. Anti-HIV seroprevalence was also evaluated with patient and tumor characteristics besides treatment regimens.


Fifty-one patients were included between September 1998 and February 2009. Male/female ratio was 3.25 (39/12). Median age was 68 (31–94). Lower extremity was the most common site whereas excisional biopsy was the most common diagnostic procedure. Smoking rate was 42.8%. Twenty percent had family history for cancer. Anti-HIV seropositivity rate was 1.9%. Thirty eight percent had local monotherapy, and radiotherapy was most common (26%). Multidisciplinary approach rate was 44%. Most of them had surgery and radiotherapy combination. Two-third of the patients had radiotherapy alone or with other modalities. Rates were as 12% for chemotherapy and 6% for interferon. Vincristine-bleomycin-doxorubicin combination was the most preferred regimen (60%).


Male patients in the sixth decade seem to have higher risk for KS. Smoking rate was almost as high. Local therapy might be sufficient in most of the patients. However, we may also consider systemic chemotherapy for selected patients, including vincristine, bleomycin and doxorubicin.


Kaposi sarcoma Treatment of Kaposi sarcoma Chemotherapy in Kaposi sarcoma Interferon in Kaposi sarcoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wang HW, Trotter MW, Lagos D et al (2004) Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 36:693Google Scholar
  2. 2.
    Hengge UR, Ruzicka T, Tyring SK et al (2002) Update on Kaposi sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2:281–292CrossRefPubMedGoogle Scholar
  3. 3.
    Dubina M, Goldenberg G (2009) Viral-associated nonmelanoma skin cancers: a review. Am J Dermatopathol 31:561–573CrossRefPubMedGoogle Scholar
  4. 4.
    Chang Y, Cesarman E, Pessin MS et al (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi sarcoma. Science 266:1865–1869CrossRefPubMedGoogle Scholar
  5. 5.
    Strichman-Almashanau L, Weltfriend S, Gideoni O (1995) No significant association between HLA antigens and classic Kaposi sarcoma: molecular analysis of 49 Jewish patients. J Clin Immunol 15: 205–209CrossRefGoogle Scholar
  6. 6.
    Mann DL, Murray C, O’Donnell M (1990) HLA antigen frequencies in HIV-1-related Kaposi sarcoma. J Acquir Immune Defic Synd 3:51–55Google Scholar
  7. 7.
    Hussein MR (2008) Immunohistological evaluation of immune cell infiltrate in cutaneous Kaposi sarcoma. Cell Biol Int 32:157–162CrossRefPubMedGoogle Scholar
  8. 8.
    Nascimento MC, de Souza VA, Sumita LM et al (2008) Prevalence of, and Risk Factors for Kaposi Sarcoma-Associated Herpesvirus Infection Among Blood Donors in Brazil: A Multi-Center Serosurvey. J Med Virology 80:1202–1210.CrossRefGoogle Scholar
  9. 9.
    Crum-Cianflone N, Hullsiek KH, Satter E et al (2009) Cutaneous malignancies among HIV-infected persons. Arch Intern Med 169:1130–1138CrossRefPubMedGoogle Scholar
  10. 10.
    Wen KW, Damania B (2009) Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett doi: 10.1016/j.canlet.2009.07.004Google Scholar
  11. 11.
    Ahmadpoor P (2009) Human herpes virus-8 and Kaposi sarcoma after kidney transplantation: mechanisms of tumor genesis. Iran J Kidney Dis 3:121–126PubMedGoogle Scholar
  12. 12.
    Piselli P, Busnach G, Citterio F et al, for the Immunosuppression and Cancer Study Group (2009) Risk of Kaposi sarcoma after solid-organ transplantation: multicenter study in 4,767 recipients in Italy, 1970–2006. Transplant Proc 41:1227–1230CrossRefPubMedGoogle Scholar
  13. 13.
    Conley LJ, Bush TJ, Buchbinder SP (1996) The association between cigarette smoking and selected HIV-related medical conditions. AIDS 10: 1121–1126PubMedGoogle Scholar
  14. 14.
    Schwartz RA (2004) Kaposi sarcoma: an update. J Surg Oncol 87:146–151CrossRefPubMedGoogle Scholar
  15. 15.
    Kapoor A (2008) Malignancy in kidney transplant recipients. Drugs 68:11–19CrossRefPubMedGoogle Scholar
  16. 16.
    Krown SE, Northfelt DW, Osoba D, Stewart JS (2004) Use of liposomal anthracyclines in Kaposi sarcoma. Semin Oncol 31:36–52CrossRefPubMedGoogle Scholar
  17. 17.
    Hengge UR, Esser S, Rudel HP, Goos M (2001) Long-term chemotherapy of HIV-associated Kaposi sarcoma with liposomal doxorubicin. Eur J Cancer 37:878–883CrossRefPubMedGoogle Scholar
  18. 18.
    Brambilla L, Romanelli A, Bellinvia M (2008) Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases. Br J Dermatol 158:1339–1344CrossRefPubMedGoogle Scholar
  19. 19.
    Ramirez-Rodriguez JM, Morgan-Villela G, Robles-Toscano JA, Echeagaray E (1996) Therapeutic response of the epidemic Kaposi Sarcoma. Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother 212 (abstract I142)Google Scholar
  20. 20.
    Silvestris N, Galeta D, Colucci G (2009) Successful treatment with three-weekly paclitaxel of an anthracycline-refractory classical Kaposi sarcoma. Anticancer Res 29:675–676PubMedGoogle Scholar
  21. 21.
    Fardet L, Stoebner PE, Bachelez H et al (2006) Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection. Cancer 106: 1785–1789CrossRefPubMedGoogle Scholar
  22. 22.
    Sullivan RJ, Pantanowitz L, Dezube BJ (2009) Targeted therapy for Kaposi sarcoma. BioDrugs 23:6975CrossRefGoogle Scholar
  23. 23.
    Berson AM, Quivey JM, Harris JW, Wara WM (1990) Radiation therapy for AIDS-related Kaposi sarcoma. Int J Radiat Oncol Biol Phys 19:569–575PubMedGoogle Scholar
  24. 24.
    Basciani S, Vona R, Matarrese P et al (2007) Imatinib interferes with survival of multidrug resistant Kaposi sarcoma cells. FEBS Lett 581:5897–5903CrossRefPubMedGoogle Scholar

Copyright information

© Feseo 2010

Authors and Affiliations

  • Mutlu Dogan
    • 1
    Email author
  • Lutfi Dogan
    • 2
  • Feyyaz Ozdemir
    • 3
  • Nuriye Yildirim Ozdemir
    • 4
  • Hasan Senol Coskun
    • 5
  • Ulku Yalcintas Arslan
    • 6
  • Guze Ozal
    • 1
  • Gungor Utkan
    • 1
  • Ahmet Demirkazik
    • 1
  • Fazil Aydin
    • 3
  • Nurullah Zengin
    • 4
  • Fikri Icli
    • 1
  1. 1.Department of Medical Oncology Cebeci HospitalAnkara University School of MedicineDikimevi, AnkaraTurkey
  2. 2.Department of General SurgeryAnkara Oncology Education and Research HospitalAnkaraTurkey
  3. 3.Department of Medical OncologyKaradeniz Technical University School of MedicineTrabzonTurkey
  4. 4.Department of Medical OncologyAnkara Numune Education and Research HospitalAnkaraTurkey
  5. 5.Department of Medical OncologyAkdeniz University School of MedicineAntalyaTurkey
  6. 6.Department of Medical OncologyAnkara Oncology Education and Research HospitalAnkaraTurkey

Personalised recommendations